Sentynl Unveils First Full Clinical Data Supporting NULIBRY® for MoCD Type A Sentynl Therapeutics, Inc. (“Sentynl”), a U.S.-based biopharmaceutical company and a wholly owned subsidiary of Zydus Lifesciences Ltd. (“Zydus Group”), has proudly announced the publication of pivotal clinical studies…
Xaira Therapeutics Appoints Bo Wang as SVP and Head of Biomedical AI In a strategic move that underscores its deepening commitment to revolutionizing drug discovery through artificial intelligence, Xaira Therapeutics has announced the appointment of Dr. Bo Wang as Senior…
Neurogene Publishes Study on NGN-401 Gene Therapy for Rett Syndrome Neurogene Inc. (Nasdaq: NGNE), a clinical-stage biotechnology company dedicated to developing transformative genetic medicines for patients suffering from rare neurological disorders, has announced the publication of a peer-reviewed study detailing…
AGC Biologics Launches New Cell & Gene Technology Division AGC Biologics, a leading Contract Development and Manufacturing Organization (CDMO), has announced the launch of its new Cell and Gene Technology division, an initiative designed to further strengthen the company’s technical…
Sydnexis Receives Positive CHMP Opinion for SYD-101 in Europe to Slow Pediatric Myopia Progression Sydnexis, Inc. a pre-commercial stage biopharmaceutical company specializing in ophthalmic therapeutics, has announced a significant regulatory milestone. The European Medicines Agency’s (EMA) Committee for Medicinal Products…
BeiGene’s TEVIMBRA® Gets CHMP Nod for First-Line Lung Cancer Treatment BeiGene, Ltd., a global oncology company soon to be rebranded as BeOne Medicines Ltd., has announced a significant milestone in its efforts to expand cancer treatment options. The Committee for…
Maternal sepsis is a life-threatening condition that arises from an infection during pregnancy, childbirth, post-abortion, or the postpartum period. It is a significant public health challenge and ranks as the third leading cause of maternal mortality worldwide. In addition to…
Halozyme Announces Positive CHMP Opinion for Bristol Myers Squibb’s Subcutaneous Opdivo® with ENHANZE Halozyme Therapeutics, Inc. (NASDAQ: HALO) recently announced a significant milestone in oncology treatment development, as Bristol Myers Squibb has received a positive opinion from the Committee for…
BMS Gets CHMP Nod for Opdivo-Based Perioperative Regimen in Resectable NSCLC Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval…
Vertex Pharmaceuticals Secures UK MHRA Approval for ALYFTREK®, a Next-Generation CFTR Modulator for Cystic Fibrosis Vertex Pharmaceuticals announced today that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor), a next-in-class, once-daily…
Merck’s SC Pembrolizumab Shows Noninferior PK to IV KEYTRUDA in Trial Merck, known as MSD outside of the United States and Canada, has presented the first data from the pivotal 3475A-D77 Phase 3 trial evaluating subcutaneous pembrolizumab in combination with…
Kardigan Acquires Prolaio to Build Innovative Heart Health Platform Kardigan, a heart health company focused on modernizing cardiovascular (CV) drug development, has announced its acquisition of Prolaio, a clinical intelligence company dedicated to advancing cardiology research and care through real-world…